Pharma Leaders
Refine Search
Latest Pharma Leaders News & Features
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted). 1 November 2023
Biotechnology
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
Biotechnology
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer and blood disorders. 20 September 2023
Biotechnology
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
Biotechnology
The need for medications that bring relief for patients affected by migraine is enormous. 26 July 2023
Biotechnology
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axicabtagene ciloleucel). 5 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Biotechnology
Earlier this month, UK biotech Bicycle Therapeutics entered a strategic collaboration with Germany’s Bayer. 26 May 2023
Biotechnology
The progress quietly made by Sino-American biotech company BeiGene with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable. 30 March 2023
Biotechnology
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
Pharmaceutical
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Prothena has an intriguing Alzheimer’s vaccine, dubbed PRX123, which is yet to enter the clinic but which scientists believe could stop the development of both Abeta and tau in the brain. 6 June 2022
Biotechnology
The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk CEO Lars Fruergaard Jørgensen takes a collegiate approach. 26 May 2022
Pharmaceutical
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
Biotechnology
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
Biotechnology
A feature on the recent fortunes of and prospects for Belgian drugmaker UCB. 25 March 2022
Biotechnology
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the approach. Dr James McIlroy, CEO of EnteroBiotix, spoke with The Pharma Letter about his firm's development strategy, and the broader potential for this therapy area. 9 March 2022
Biotechnology
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episode, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI. 30 December 2021
Pharmaceutical
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
Pharmaceutical
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective treatments available, the outcome is often a burdensome impact on quality of life. 15 June 2021
Biotechnology
Interest in the therapeutic potential of psychedelics is at an all-time high. 11 May 2021
Biotechnology
Danish company Genmab has a lot going on this year, as chief executive Jan van de Winkel tells The Pharma Letter. 16 April 2021
Biotechnology
Californian aging specialist CohBar is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for ageing” at some point. 23 March 2021
Pharmaceutical
Large, privately-held European drugmakers are not typically identified with dynamism and a bold, acquisitive business strategy. 22 January 2021
Biotechnology
Impressive data for another immuno-oncology / tyrosine kinase inhibitor (TKI) combo add up to yet more competition in the first-line kidney cancer setting. 21 September 2020
Pharmaceutical
While vaccine developers including Moderna Therapeutics and AstraZeneca have reported promising results from their COVID-19 programs, the world urgently needs better options for the large number of people being hospitalized with the disease. 17 July 2020
Pharmaceutical
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken by US biotech Tetra Therapeutics. 17 February 2020
Biotechnology
As biotech companies making themselves eligible to a big pharma buyout go, Imugene appears to tick a lot of the boxes – but the proof of the pudding will come with all important trial results. 24 January 2020
Biotechnology
Chinese biotech start-up Antengene recently hired two former high-profile managers from its funding partner Celgene, now a Bristol-Myers Squibb (NYSE: BMY) company. In a recent meeting in Shanghai, where Antengene is based, founder and chief executive Jay Mei spoke with The Pharma Letter about the hires and his vision for his company. 16 January 2020
Biosimilars
Biosimilars manufacturers can get a bad rap.
Derided as offering mere "copycats," piggybacking off the success of true innovators, companies such as South Korea's Samsung Bioepis have struggled to break into established markets that favor brand names. 6 December 2019
Biotechnology
Orchard Therapeutics has big ambitions for its role in pioneering some of the most advanced treatments in development today. 25 November 2019
Biotechnology
In March 2019, after a series of political convolutions worthy of a Choose Your Own Adventure novel, former UK Prime Minister Theresa May finally managed to bring her country, and its complaining industries, to the brink of Brexit. 23 October 2019
Pharmaceutical
As the dust settles on 2019’s annual meeting of the European Society of Medical Oncology (ESMO), data from several candidates give hope that the burden of disease may soon be alleviated for millions of people diagnosed with bladder cancer. 4 October 2019
Pharmaceutical
Pivotal data from a Phase II study of the FGFR inhibitor pemigatinib will be used to support a US filing later in the year, says Incyte chief executive Hervé Hoppenot. 27 September 2019
Biotechnology
In Cambridge, USA, just around the corner from fellow gene therapy specialist bluebird bio, a less well-known biotech startup could be about to shake up the market for certain rare disease therapies. 24 September 2019
Biotechnology
Investors in the Atlas Venture-backed immuno-oncology specialist Surface Oncology have had a rough time since the company went public in New York, early in 2018. 5 September 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze